{"title":"通过治疗进步提高生活质量。医药类股消息:Ipsen N.V.","authors":"","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>IPSEN is the Belgian subsidiary of the independent European pharmaceutical company Beaufour Ipsen, founded in 1929 by Dr. Henri Beaufour. With an expanding international presence, the group invests almost 20% of group turnover in research and development of high technology ethical products. Beaufour Ipsen R & D's fundamental goal is quality of life for patients with a special emphasis on homeostatic regulation, achieving the optimal efficacy versus tolerance ratio.</p>","PeriodicalId":75424,"journal":{"name":"Acta urologica Belgica","volume":"66 2","pages":"21-2"},"PeriodicalIF":0.0000,"publicationDate":"1998-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Quality of life through therapeutic advances. Pharmaceutical company news: Ipsen N.V.\",\"authors\":\"\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>IPSEN is the Belgian subsidiary of the independent European pharmaceutical company Beaufour Ipsen, founded in 1929 by Dr. Henri Beaufour. With an expanding international presence, the group invests almost 20% of group turnover in research and development of high technology ethical products. Beaufour Ipsen R & D's fundamental goal is quality of life for patients with a special emphasis on homeostatic regulation, achieving the optimal efficacy versus tolerance ratio.</p>\",\"PeriodicalId\":75424,\"journal\":{\"name\":\"Acta urologica Belgica\",\"volume\":\"66 2\",\"pages\":\"21-2\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1998-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta urologica Belgica\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta urologica Belgica","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Quality of life through therapeutic advances. Pharmaceutical company news: Ipsen N.V.
IPSEN is the Belgian subsidiary of the independent European pharmaceutical company Beaufour Ipsen, founded in 1929 by Dr. Henri Beaufour. With an expanding international presence, the group invests almost 20% of group turnover in research and development of high technology ethical products. Beaufour Ipsen R & D's fundamental goal is quality of life for patients with a special emphasis on homeostatic regulation, achieving the optimal efficacy versus tolerance ratio.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
